TYPE: 8-K
SEQUENCE: 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 19, 1998
EXTEN INDUSTRIES, INC.
(Exact name or registrant as specified in its charter)
Delaware 0-16354 52-1412493
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation or file number) Identification No.)
organization)
9625 Black Mountain Road, Suite 218, San Diego, California 92126
(Address of principal executive offices) (Zip Code)
9625 Black Mountain Road, Suite 218, San Diego, California 92126
(Mailing Address) (Zip Code)
Registrant's telephone number, including area code: (619)578-9784
Item 5. Other Events.
On March 10, 1998, Exten Industries, Inc. (Exten) announced that
it had signed an agreement with Loyola University in Chicago. Jim
Considine, MD MBA, President, Xenogenics Corporation, and John
Brems, MD FACS, Chairman of the Xenogenics Scientific Advisory
Board and Director, Transplantation, Loyola University, Chicago
Stritch School of Medicine announced today that a research
agreement has been signed between the two organizations. Loyola
will shortly begin pre-clinical testing of the SybiolR bio
artificial liver support technology under the direction of James
Filkins, Ph.D., Professor Emeritus, Loyola University School of
Medicine. Dr. Filkins is also a member of the Xenogenics
Scientific Advisory Board.
The research agreement is expected to commence sometime in the
second quarter of 1998. Consummation of the transaction is
conditioned upon obtaining all necessary governmental and
regulatory consents and other customary conditions. The board
of directors of Exten and Loyola have approved the agreement. A
copy of the March 10, 1998, press release is included herewith as
an exhibit.
Item 7. Financial Statements and Exhibits.
99.1 Press Release.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of
the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
EXTEN INDUSTRIES, INC.
(Registrant)
By: /s/ W. GERALD NEWMIN
-----------------------------
Chairman, Chief Executive Officer
and President
Date: March 23, 1998
TYPE: EX-99
SEQUENCE: 2
DESCRIPTION: PRESS RELEASE
- -----------------------------------------------------------------
FOR FURTHER INFORMATION:
- -----------------------------------------------------------------
NEWS
FOR IMMEDIATE RELEASE:
March 10, 1998 CONTACTS:
At Xenogenics Corporation:
Dr. Jim Considine, President
(714)451-1500
At Exten Industries, Inc.
W. Gerald Newmin, President
Barbara Corbett, Marketing Mgr.
(619)578-9784
After hours:(619)455-7205, 423-3737
Xenogenics Corporation and Loyola University
Sign Research Agreement
San Diego, March 10, 1998
Jim Considine, MD MBA, President, Xenogenics Corporation, and
John Brems, MD FACS, Chairman of the Xenogenics Scientific
Advisory Board and Director, Transplantation, Loyola University,
Chicago Stritch School of Medicine announced today that a
research agreement has been signed between the two organizations.
Loyola will shortly begin pre-clinical testing of the SybiolR
bioartificial liver support technology under the direction of
James Filkins, Ph.D., Professor Emeritus, Loyola University
School of Medicine. Dr. Filkins is also a member of the
Xenogenics Scientific Advisory Board.
The proprietary SybiolR synthetic bioartificial liver (patent
pending) is intended to be used as an "artificial liver" to
support transplant candidates when no organ donor is available.
It would also be used for post transplant stabilization as well
as treatment of toxicity secondary to both chronic liver disease
and acute hepatotoxic agents. The device is intended to perform a
function for the liver similar to that which renal dialysis
performs for kidneys. A key difference is the proposed usage of
porcine (piglet) hepatocytes (liver cells)to provide continuous,
sustained removal of human blood toxins outside the liver.
Loyola has recently assembled a team of bioartificial liver
researchers including Drs. Brems and Filkins, as well as David
Van Thiel, MD, FACP, Professor, Internal Medicine, Loyola
University Medical Center. Dr. Van Thiel was a key architect
along with Dr. Thomas Starzl in the development of the liver
transplant program at the University of Pittsburgh in the 1980s.
Dr. Considine commented, "The initiation of the research
agreement with the liver team at Loyola constitutes an important
milestone for Xenogenics Corporation and Exten Industries. We
look forward to a long and successful relationship with the
Loyola Research Group."
Xenogenics Corp. is a 100% owned subsidiary of Exten Industries,
Inc. (OTC-BB:EXTI) located at 9625 Black Mountain Rd., Suite.
218, San Diego, CA 92126-4564. For further information call Jerry
Newmin or Barbara Corbett: (619) 578-9784 or e-mail at
[email protected]. Exten's web site is http://www.exten.com.
************
The matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially. These risks
are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission including the
Company's Annual Report, Quarterly Reports and other periodic
filings. These forward-looking statements speak only as of the
date hereof. The Company disclaims any intent or obligation to
update these forward-looking statements.
